341 related articles for article (PubMed ID: 24253450)
1. Binding and inhibition of drug transport proteins by heparin: a potential drug transporter modulator capable of reducing multidrug resistance in human cancer cells.
Chen Y; Scully M; Petralia G; Kakkar A
Cancer Biol Ther; 2014 Jan; 15(1):135-45. PubMed ID: 24253450
[TBL] [Abstract][Full Text] [Related]
2. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
Dai CL; Tiwari AK; Wu CP; Su XD; Wang SR; Liu DG; Ashby CR; Huang Y; Robey RW; Liang YJ; Chen LM; Shi CJ; Ambudkar SV; Chen ZS; Fu LW
Cancer Res; 2008 Oct; 68(19):7905-14. PubMed ID: 18829547
[TBL] [Abstract][Full Text] [Related]
3. Human ABCB1 (P-glycoprotein) and ABCG2 mediate resistance to BI 2536, a potent and selective inhibitor of Polo-like kinase 1.
Wu CP; Hsiao SH; Sim HM; Luo SY; Tuo WC; Cheng HW; Li YQ; Huang YH; Ambudkar SV
Biochem Pharmacol; 2013 Oct; 86(7):904-13. PubMed ID: 23962445
[TBL] [Abstract][Full Text] [Related]
4. TTFields alone and in combination with chemotherapeutic agents effectively reduce the viability of MDR cell sub-lines that over-express ABC transporters.
Schneiderman RS; Shmueli E; Kirson ED; Palti Y
BMC Cancer; 2010 May; 10():229. PubMed ID: 20492723
[TBL] [Abstract][Full Text] [Related]
5. Reversal effect of FW-04-806, a macrolide dilactone compound, on multidrug resistance mediated by ABCB1 and ABCG2 in vitro and in vivo.
Zhang Z; Ma C; Li P; Wu M; Ye S; Fu L; Xu J
Cell Commun Signal; 2019 Sep; 17(1):110. PubMed ID: 31472682
[TBL] [Abstract][Full Text] [Related]
6. β-carotene reverses multidrug resistant cancer cells by selectively modulating human P-glycoprotein function.
Teng YN; Sheu MJ; Hsieh YW; Wang RY; Chiang YC; Hung CC
Phytomedicine; 2016 Mar; 23(3):316-23. PubMed ID: 26969385
[TBL] [Abstract][Full Text] [Related]
7. Multidrug resistance: retrospect and prospects in anti-cancer drug treatment.
Pérez-Tomás R
Curr Med Chem; 2006; 13(16):1859-76. PubMed ID: 16842198
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of P-glycoprotein functionality by vandetanib may reverse cancer cell resistance to doxorubicin.
Jovelet C; Bénard J; Forestier F; Farinotti R; Bidart JM; Gil S
Eur J Pharm Sci; 2012 Aug; 46(5):484-91. PubMed ID: 22484209
[TBL] [Abstract][Full Text] [Related]
9. Dacomitinib antagonizes multidrug resistance (MDR) in cancer cells by inhibiting the efflux activity of ABCB1 and ABCG2 transporters.
Fan YF; Zhang W; Zeng L; Lei ZN; Cai CY; Gupta P; Yang DH; Cui Q; Qin ZD; Chen ZS; Trombetta LD
Cancer Lett; 2018 May; 421():186-198. PubMed ID: 29331420
[TBL] [Abstract][Full Text] [Related]
10. Multidrug resistance transporters and modulation.
Tan B; Piwnica-Worms D; Ratner L
Curr Opin Oncol; 2000 Sep; 12(5):450-8. PubMed ID: 10975553
[TBL] [Abstract][Full Text] [Related]
11. Acyl-CoA synthetase-4 is implicated in drug resistance in breast cancer cell lines involving the regulation of energy-dependent transporter expression.
Orlando UD; Castillo AF; Medrano MAR; Solano AR; Maloberti PM; Podesta EJ
Biochem Pharmacol; 2019 Jan; 159():52-63. PubMed ID: 30414939
[TBL] [Abstract][Full Text] [Related]
12. Sensitization of ABCB1 overexpressing cells to chemotherapeutic agents by FG020326 via binding to ABCB1 and inhibiting its function.
Dai CL; Liang YJ; Chen LM; Zhang X; Deng WJ; Su XD; Shi Z; Wu CP; Ashby CR; Akiyama S; Ambudkar SV; Chen ZS; Fu LW
Biochem Pharmacol; 2009 Aug; 78(4):355-64. PubMed ID: 19410561
[TBL] [Abstract][Full Text] [Related]
13. Jadomycins are cytotoxic to ABCB1-, ABCC1-, and ABCG2-overexpressing MCF7 breast cancer cells.
Issa ME; Hall SR; Dupuis SN; Graham CL; Jakeman DL; Goralski KB
Anticancer Drugs; 2014 Mar; 25(3):255-69. PubMed ID: 24231527
[TBL] [Abstract][Full Text] [Related]
14. The Pim kinase inhibitor SGI-1776 decreases cell surface expression of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and drug transport by Pim-1-dependent and -independent mechanisms.
Natarajan K; Bhullar J; Shukla S; Burcu M; Chen ZS; Ambudkar SV; Baer MR
Biochem Pharmacol; 2013 Feb; 85(4):514-24. PubMed ID: 23261525
[TBL] [Abstract][Full Text] [Related]
15. The novel BCR-ABL and FLT3 inhibitor ponatinib is a potent inhibitor of the MDR-associated ATP-binding cassette transporter ABCG2.
Sen R; Natarajan K; Bhullar J; Shukla S; Fang HB; Cai L; Chen ZS; Ambudkar SV; Baer MR
Mol Cancer Ther; 2012 Sep; 11(9):2033-44. PubMed ID: 22778153
[TBL] [Abstract][Full Text] [Related]
16. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.
Shi Z; Peng XX; Kim IW; Shukla S; Si QS; Robey RW; Bates SE; Shen T; Ashby CR; Fu LW; Ambudkar SV; Chen ZS
Cancer Res; 2007 Nov; 67(22):11012-20. PubMed ID: 18006847
[TBL] [Abstract][Full Text] [Related]
17. Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin.
Limtrakul P; Chearwae W; Shukla S; Phisalphong C; Ambudkar SV
Mol Cell Biochem; 2007 Feb; 296(1-2):85-95. PubMed ID: 16960658
[TBL] [Abstract][Full Text] [Related]
18. The association of increased lung resistance protein expression with acquired etoposide resistance in human H460 lung cancer cell lines.
Lee E; Lim SJ
Arch Pharm Res; 2006 Nov; 29(11):1018-23. PubMed ID: 17146971
[TBL] [Abstract][Full Text] [Related]
19. A very early induction of major vault protein accompanied by increased drug resistance in U-937 cells.
Hu Y; Stephen AG; Cao J; Tanzer LR; Slapak CA; Harrison SD; Devanarayan V; Dantzig AH; Starling JJ; Rome LH; Moore RE
Int J Cancer; 2002 Jan; 97(2):149-56. PubMed ID: 11774257
[TBL] [Abstract][Full Text] [Related]
20. Nilotinib enhances the efficacy of conventional chemotherapeutic drugs in CD34⁺CD38⁻ stem cells and ABC transporter overexpressing leukemia cells.
Wang F; Wang XK; Shi CJ; Zhang H; Hu YP; Chen YF; Fu LW
Molecules; 2014 Mar; 19(3):3356-75. PubMed ID: 24651611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]